Wiley Bros. Aintree Capital, LLC Bei Gene, Ltd. Transaction History
Wiley Bros. Aintree Capital, LLC
- $8.04 Billion
- Q4 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 1,532 shares of BGNE stock, worth $347,319. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,532
Previous 1,033
48.31%
Holding current value
$347,319
Previous $231,000
22.08%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
254Shares Held
42.4MCall Options Held
135KPut Options Held
111K-
Baker Bros. Advisors LP New York, NY9.53MShares$2.16 Billion19.52% of portfolio
-
Capital International Investors Los Angeles, CA6.11MShares$1.39 Billion0.22% of portfolio
-
Primecap Management CO Pasadena, CA5.1MShares$1.16 Billion0.74% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.8MShares$862 Million26.88% of portfolio
-
Baillie Gifford & CO3.67MShares$832 Million0.54% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...